Phase I Dose Escalation and Pharmacokinetic Study of SSR97225 Administered as a 1 Hour IV Infusion D1 Every 3 Weeks (Arm A) or Administered as a 1hour IV Infusion D1, D8, D15 Every 3 Weeks (Arm B) in Patients With Refractory Solid Tumors

Inclusion Criteria:

- Diagnosis of metastatic or locally advanced non-hematological cancer

- Patients with solid tumors refractory to therapy or for whom no therapy exists

Exclusion Criteria:

- Five or more prior chemotherapy lines for metastatic disease

- Eastern Cooperative Oncology Group (ECOG) performance status >2

- Patients having discontinued previous specific anti-cancer treatment

- Patients who have not recovered from all toxic effects from previous specific
anti-cancer treatment (excluding alopecia)

- Patients with abnormal biological/hematological parameters, cardiac abnormalities or
serious infection/intercurrent illness likely to jeopardize the patient's safety or
the course of the protocol treatment

- No adequate birth control methods

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.